These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28237896)

  • 1. Towards toxicokinetic modelling of aluminium exposure from adjuvants in medicinal products.
    Weisser K; Stübler S; Matheis W; Huisinga W
    Regul Toxicol Pharmacol; 2017 Aug; 88():310-321. PubMed ID: 28237896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Critical analysis of reference studies on aluminium-based adjuvants toxicokinetics].
    Masson JD; Crépeaux G; Authier FJ; Exley C; Gherardi RK
    Ann Pharm Fr; 2017 Jul; 75(4):245-256. PubMed ID: 28576261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aluminium toxicokinetics after intramuscular, subcutaneous, and intravenous injection of Al citrate solution in rats.
    Weisser K; Göen T; Oduro JD; Wangorsch G; Hanschmann KO; Keller-Stanislawski B
    Arch Toxicol; 2019 Jan; 93(1):37-47. PubMed ID: 30302509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical analysis of reference studies on the toxicokinetics of aluminum-based adjuvants.
    Masson JD; Crépeaux G; Authier FJ; Exley C; Gherardi RK
    J Inorg Biochem; 2018 Apr; 181():87-95. PubMed ID: 29307441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insight into the cellular fate and toxicity of aluminium adjuvants used in clinically approved human vaccinations.
    Mold M; Shardlow E; Exley C
    Sci Rep; 2016 Aug; 6():31578. PubMed ID: 27515230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo absorption of aluminium-containing vaccine adjuvants using 26Al.
    Flarend RE; Hem SL; White JL; Elmore D; Suckow MA; Rudy AC; Dandashli EA
    Vaccine; 1997; 15(12-13):1314-8. PubMed ID: 9302736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. When an aluminium adjuvant is not an aluminium adjuvant used in human vaccination programmes.
    Exley C
    Vaccine; 2012 Mar; 30(12):2042. PubMed ID: 22041301
    [No Abstract]   [Full Text] [Related]  

  • 8. Aluminium in allergen-specific subcutaneous immunotherapy--a German perspective.
    Kramer MF; Heath MD
    Vaccine; 2014 Jul; 32(33):4140-8. PubMed ID: 24892252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aluminium-adjuvanted vaccines--a review of the current state of knowledge.
    Gołoś A; Lutyńska A
    Przegl Epidemiol; 2015; 69(4):731-4, 871-4. PubMed ID: 27139352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elimination of aluminum adjuvants.
    Hem SL
    Vaccine; 2002 May; 20 Suppl 3():S40-3. PubMed ID: 12184363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aluminium assay and evaluation of the local reaction at several time points after intramuscular administration of aluminium containing vaccines in the Cynomolgus monkey.
    Verdier F; Burnett R; Michelet-Habchi C; Moretto P; Fievet-Groyne F; Sauzeat E
    Vaccine; 2005 Feb; 23(11):1359-67. PubMed ID: 15661384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aluminium toxicokinetics: an updated minireview.
    Yokel RA; McNamara PJ
    Pharmacol Toxicol; 2001 Apr; 88(4):159-67. PubMed ID: 11322172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aluminium overload after 5 years in skin biopsy following post-vaccination with subcutaneous pseudolymphoma.
    Guillard O; Fauconneau B; Pineau A; Marrauld A; Bellocq JP; Chenard MP
    J Trace Elem Med Biol; 2012 Oct; 26(4):291-3. PubMed ID: 22425036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. About the alleged toxicity of aluminium-based adjuvants in vaccines: All published studies should be taken into account.
    Goullé JP; Couvreur P; Grangeot-Keros L
    Int J Pharm; 2021 Jun; 602():120656. PubMed ID: 33932540
    [No Abstract]   [Full Text] [Related]  

  • 15. A role for the body burden of aluminium in vaccine-associated macrophagic myofasciitis and chronic fatigue syndrome.
    Exley C; Swarbrick L; Gherardi RK; Authier FJ
    Med Hypotheses; 2009 Feb; 72(2):135-9. PubMed ID: 19004564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aluminium compounds for use in vaccines.
    Lindblad EB
    Immunol Cell Biol; 2004 Oct; 82(5):497-505. PubMed ID: 15479435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of aluminum adjuvant toxicity and autoimmunity in pediatric populations.
    Tomljenovic L; Shaw CA
    Lupus; 2012 Feb; 21(2):223-30. PubMed ID: 22235057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of aluminium in rat following administration of allergen immunotherapy using either aluminium or microcrystalline-tyrosine-based adjuvants.
    McDougall SA; Heath MD; Kramer MF; Skinner MA
    Bioanalysis; 2016 Mar; 8(6):547-56. PubMed ID: 26915397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraperitoneal administration of aluminium-based adjuvants produces severe transient systemic adverse events in mice.
    Freiberger SN; Leuthard DS; Duda A; Contassot E; Thallmair M; Kündig TM; Johansen P
    Eur J Pharm Sci; 2018 Mar; 115():362-368. PubMed ID: 29410031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Aluminium adjuvant exposure through vaccines in France in 2018].
    Angrand L; Elnar AA; Authier FJ; Gherardi RK; Crépeaux G
    Ann Pharm Fr; 2020 Mar; 78(2):111-128. PubMed ID: 32081303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.